2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Matthew S. McKinney, MD, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Matthew S. McKinney, MD, cellular therapy specialist, hematologic oncologist, hematologist (malignant), Duke Health, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma (MCL).
The FDA approval of brexucabtagene autoleucel (Tecartus) represented the first CD19-directed CAR T-cell therapy available for use in patients with relapsed/refractory MCL. The therapy appears more efficacious and has shown prolonged survival compared with other available therapies for this patient population, McKinney says.
Despite the excitement surrounding CAR T-cell therapy, questions regarding optimal sequencing and patient selection remain unanswered, McKinney explains. Not all patients with MCL will be eligible for CAR T-cell therapy for reasons including frailty, caregiver status, or inadequate lymphocyte collection.
Clinical trials are evaluating whether CAR T-cell therapy should be sequenced in the second-line setting before or with BTK inhibitors, McKinney concludes.
Related Content: